L'Oreal USA, the largest subsidiary of the world's leading beauty company, has inked pact with 3-D bioprinting company Organovo Holdings, Inc.
Developed between L'Oreal's US-based Global Technology Incubator and Organovo, the collaboration will leverage Organovo's proprietary NovoGen bioprinting platform and L'Oreal's expertise in skin engineering to develop 3-D printed skin tissue for product evaluation and other areas of advanced research.
This partnership marks the first-ever application of Organovo's groundbreaking technology within the beauty industry.
"We developed our technology incubator to uncover disruptive innovations across industries that have the potential to transform the beauty business," said Guive Balooch, global vice president of L'Oreal's Technology Incubator.
"Organovo has broken new ground with 3-D bioprinting, an area that complements L'Oreal's pioneering work in the research and application of reconstructed skin for the past 30 years. Our partnership will not only bring about new advanced in vitro methods for evaluating product safety and performance, but the potential for where this new field of technology and research can take us is boundless."
Organovo's 3D bioprinting enables the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body.
"We are excited to be partnering with L'Oreal, whose leadership in the beauty industry is rooted in scientific innovation and a deep commitment to research and development," said Keith Murphy, chairman and chief executive officer at Organovo. "This partnership is a great next step to expand the applications of Organovo's 3-D bioprinting technology and to create value for both L'Oreal and Organovo by building new breakthroughs in skin modeling."